Advertisement

Neurodegenerative diseases: CSF amines, lactate and clinical findings

  • E. Sofic
  • J. Fritze
  • G. Schnaberth
  • J. Bruck
  • P. Riederer
Part of the Key Topics in Brain Research book series (KEYTOPICS)

Summary

Biogenic amines and their metabolites in lumbar CSF and serum from 43 patients did not significantly differ between dementia of Alzheimer’s type (DAT), Binswanger’s disease (BD), multiinfarct dementia (MID) and Parkinson’s disease (PD). The only significant finding was elevated CSF 5-hydroxyindoleacetic acid (5HIAA) in DAT patients treated with neuroleptics relative to the other groups. The values found in a small number of patients with Pick’s, Huntington’s (CH) and Creutzfeldt-Jacob’s (CJ) disease were within the range of the other groups. CSF lactate, measured in 28 of the patients, tended to be elevated in vascular dementia (BD, MID). A crude estimate of cognitive impairment showed correlations to inner and outer brain atrophy in CT-scans. There were, however, no definite correlations between clinical impairments and CSF or serum findings.

Keywords

Biogenic Amine Vascular Dementia Monoamine Metabolite Plasma Homovanillic Acid Monoamine Metabolite Concentration 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Beal MF, Growdon JH (1986) CSF neurotransmitter markers in Alzheimer’s disease. Prog Neuropsychopharmacol Biol Psychiatry 10: 259–270PubMedCrossRefGoogle Scholar
  2. Cummings JL (1986) Subcortical dementia. Br J Psychiatry 149: 682–697PubMedCrossRefGoogle Scholar
  3. Davidson M, Giordani AB, Mohs RC, Mykytyn VV, Platt S, Aryan ZS, Davis KL (1987) Control of exogenous factors affecting plasma homovanillic acid concentration. Psychiatry Res 20: 307–312PubMedCrossRefGoogle Scholar
  4. Gibb WRG (1989) Dementia and Parkinson’s disease. Br J Psychiatry 154: 596614Google Scholar
  5. Gibson CJ, Logue M, Growdon MD (1985) CSF monoamine metabolite levels in Alzheimer’s and Parkinson’s disease. Arch Neurol 42: 489–492PubMedCrossRefGoogle Scholar
  6. Gottfries CG (1985) Alzheimer’s disease and senile dementia: biochemical characteristics and aspects of treatment. Psychopharmacology 86: 245–252PubMedCrossRefGoogle Scholar
  7. Hollander E, Mohs RC, Davis KL (1986) Antemortem markers of Alzheimer’s disease. Neurobiol Aging 7: 367–387PubMedCrossRefGoogle Scholar
  8. Kurlan R, Caine E, Rubin A, Nemeroff CB, Bissette G, Zaczek R, Coyle J, Spielman FJ, Irvine C, Shoulson I (1988) Cerebrospinal fluid correlates of depression in Huntington’s disease. Arch Neurol 45: 881–883PubMedCrossRefGoogle Scholar
  9. Miller Fisher C (1989) Binswanger’s encephalopathy: a review. J Neurol 256: 65–79CrossRefGoogle Scholar
  10. Mann MA, Yates PO (1986) Neurotransmitter deficits in Alzheimer’s disease and in other dementing disorders. Human Neurobiol 5: 147–158Google Scholar
  11. Palmer AM, Sims NR, Bowen DM, Neary D, Palo J, Wikstrom J, Davison AN (1984) Monoamine metabolite concentrations in lumbar cerebrospinal fluid of patients with histologically verified Alzheimer’s dementia. J Neurol Neurosurg Psychiatry 47: 481–484PubMedCrossRefGoogle Scholar
  12. Riederer P, Rausch WD, Schmidt B, Kruzik P, Konradi C, Sofic E, Danielczyk W (1988) Biochemical fundamentals of Parkinson’s disease. Mt Sinai J Med (NY) 55: 21–28Google Scholar
  13. Rossor M (1988) Neurochemical studies in dementia. In: Iversen LL, Iversen SD, Snyder SH (eds) Handbook of psychopharmacology, vol 20. Psychopharmacology of the aging nervous system. Plenum Press, New York London, pp 107 —130Google Scholar
  14. Sanberg PR, Coyle JT (1984) Scientific approaches to Huntington’s disease. Crit Rev Clin Neurobiol 1: 1–44Google Scholar
  15. Sofic E (1986) Untersuchungen von biogenen Aminen, Metaboliten, Ascorbinsäure und Glutathion mittels HPLC-ECD und deren Verhalten in ausgewählten Lebensmitteln und im Organismus von Mensch und Tier. Thesis, TU ViennaGoogle Scholar
  16. Turkka JV, Juujärvi KK, Lapinlampi TO, Myllylä VV (1986) Serum nor-adrenaline response to standing up in patients with Parkinson’s disease. Eur Neurol 25:355 —361Google Scholar

Copyright information

© Springer-Verlag Wien 1990

Authors and Affiliations

  • E. Sofic
    • 1
  • J. Fritze
    • 2
  • G. Schnaberth
    • 3
  • J. Bruck
    • 3
  • P. Riederer
    • 1
  1. 1.Section on Clinical NeurochemistryUniversity of WürzburgFederal Republic of Germany
  2. 2.Department of PsychiatryUniversity of WürzburgFederal Republic of Germany
  3. 3.Ludwig-Boltzmann-Institut zur Erforschung kindlicher HirnschädenNeurologisches Krankenhaus RosenhügelViennaAustria

Personalised recommendations